TY - JOUR AU - Isaacs, A. AU - Lindenmann, J. PY - 1957 DA - 1957// TI - Virus interference. I. the interferon JO - Proc R Soc London Ser B, Biol Sci VL - 147 UR - https://doi.org/10.1098/rspb.1957.0048 DO - 10.1098/rspb.1957.0048 ID - Isaacs1957 ER - TY - JOUR AU - Devonshire, V. AU - Lapierre, Y. AU - Macdonell, R. AU - Ramo-Tello, C. AU - Patti, F. AU - Fontoura, P. PY - 2011 DA - 2011// TI - The global adherence project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis JO - Eur J Neurol VL - 18 UR - https://doi.org/10.1111/j.1468-1331.2010.03110.x DO - 10.1111/j.1468-1331.2010.03110.x ID - Devonshire2011 ER - TY - JOUR AU - Hartung, H. -. P. PY - 2014 DA - 2014// TI - Interferon β-1a for multiple sclerosis: old drug, new clothes JO - Lancet Neurol VL - 13 UR - https://doi.org/10.1016/S1474-4422(14)70100-0 DO - 10.1016/S1474-4422(14)70100-0 ID - Hartung2014 ER - TY - JOUR AU - Baker, D. P. AU - Pepinsky, R. B. AU - Brickelmaier, M. AU - Gronke, R. S. AU - Hu, X. AU - Olivier, K. PY - 2010 DA - 2010// TI - PEGylated interferon beta-1a: meeting an unmet medical need in the treatment of relapsing multiple sclerosis JO - J Interf Cytokine Res VL - 30 UR - https://doi.org/10.1089/jir.2010.0092 DO - 10.1089/jir.2010.0092 ID - Baker2010 ER - TY - JOUR AU - Zeuzem, S. AU - Welsch, C. AU - Herrmann, E. AU - Ph, D. PY - 2003 DA - 2003// TI - Pharmacokinetics of peginterferons JO - Semin Liver Dis VL - 23 UR - https://doi.org/10.1055/s-2003-41631 DO - 10.1055/s-2003-41631 ID - Zeuzem2003 ER - TY - JOUR AU - Zeuzem, S. AU - Feinman, V. R. AU - Heathcote, J. AU - Ming-Yang, L. AU - Gane, D. AU - O’grady, J. PY - 2000 DA - 2000// TI - Peginterferon alfa-2a in patients with chronic hepatitis C JO - N Engl J Med VL - 343 UR - https://doi.org/10.1056/NEJM200012073432301 DO - 10.1056/NEJM200012073432301 ID - Zeuzem2000 ER - TY - JOUR AU - Lindsay, K. L. AU - Trepo, C. AU - Heintges, T. AU - Shiffman, M. L. AU - Gordon, S. C. AU - Hoefs, J. C. PY - 2001 DA - 2001// TI - A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C JO - Hepatology. VL - 34 UR - https://doi.org/10.1053/jhep.2001.26371 DO - 10.1053/jhep.2001.26371 ID - Lindsay2001 ER - TY - JOUR AU - Hu, X. AU - Miller, L. AU - Richman, S. AU - Hitchman, S. AU - Glick, G. AU - Liu, S. PY - 2012 DA - 2012// TI - A novel PEGylated interferon Beta-1a for multiple sclerosis: safety, pharmacology, and biology JO - J Clin Pharmacol VL - 52 UR - https://doi.org/10.1177/0091270011407068 DO - 10.1177/0091270011407068 ID - Hu2012 ER - TY - JOUR AU - Hu, X. AU - Shang, S. AU - Nestorov, I. AU - Hasan, J. AU - Seddighzadeh, A. AU - Dawson, K. PY - 2016 DA - 2016// TI - COMPARE: pharmacokinetic profiles of subcutaneous peginterferon beta-1a and subcutaneous interferon beta-1a over 2 weeks in healthy subjects JO - Br J Clin Pharmacol VL - 82 UR - https://doi.org/10.1111/bcp.12968 DO - 10.1111/bcp.12968 ID - Hu2016 ER - TY - JOUR AU - Kieseier, B. C. AU - Arnold, D. L. AU - Balcer, L. J. AU - Boyko, A. A. AU - Pelletier, J. AU - Liu, S. PY - 2015 DA - 2015// TI - Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE JO - Mult Scler VL - 21 UR - https://doi.org/10.1177/1352458514557986 DO - 10.1177/1352458514557986 ID - Kieseier2015 ER - TY - BOOK AU - Fiore, D. PY - 2016 DA - 2016// TI - ADVANCE phase 3 extension study (ATTAIN): Peginterferon beta-1a 125 mcg every 2 weeks demonstrated sustained efficacy in RMS patients treated up to 5 years. AAN ID - Fiore2016 ER - TY - JOUR AU - Calabresi, P. A. AU - Kieseier, B. C. AU - Arnold, D. L. AU - Balcer, L. J. AU - Boyko, A. AU - Pelletier, J. PY - 2014 DA - 2014// TI - Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study JO - Lancet Neurol VL - 13 UR - https://doi.org/10.1016/S1474-4422(14)70068-7 DO - 10.1016/S1474-4422(14)70068-7 ID - Calabresi2014 ER - TY - JOUR AU - Kappos, L. AU - Wiendl, H. AU - Selmaj, K. AU - Arnold, D. L. AU - Havrdova, E. AU - Boyko, A. PY - 2015 DA - 2015// TI - Daclizumab HYP versus interferon Beta-1a in relapsing multiple sclerosis JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1501481 DO - 10.1056/NEJMoa1501481 ID - Kappos2015 ER - TY - JOUR AU - Balak, D. M. AU - Hengstman, G. J. AU - Cakmak, A. AU - Thio, H. B. PY - 2012 DA - 2012// TI - Cutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: a systematic review JO - Mult Scler J VL - 18 UR - https://doi.org/10.1177/1352458512438239 DO - 10.1177/1352458512438239 ID - Balak2012 ER - TY - JOUR AU - Kolb-Mäurer, A. AU - Goebeler, M. AU - Mäurer, M. PY - 2015 DA - 2015// TI - Cutaneous adverse events associated with interferon-β treatment of multiple sclerosis JO - Int J Mol Sci VL - 16 UR - https://doi.org/10.3390/ijms160714951 DO - 10.3390/ijms160714951 ID - Kolb-Mäurer2015 ER - TY - JOUR AU - Buttmann, M. AU - Goebeler, M. AU - Toksoy, A. AU - Schmid, S. AU - Graf, W. AU - Berberich-Siebelt, F. PY - 2005 DA - 2005// TI - Subcutaneous interferon-β injections in patients with multiple sclerosis initiate inflammatory skin reactions by local chemokine induction JO - J Neuroimmunol VL - 168 UR - https://doi.org/10.1016/j.jneuroim.2005.07.011 DO - 10.1016/j.jneuroim.2005.07.011 ID - Buttmann2005 ER - TY - JOUR AU - Walther, E. U. AU - Hohlfeld, R. PY - 1999 DA - 1999// TI - Multiple sclerosis: side effects of interferon beta therapy and their management JO - Neurology. VL - 53 UR - https://doi.org/10.1212/WNL.53.8.1622 DO - 10.1212/WNL.53.8.1622 ID - Walther1999 ER - TY - JOUR AU - Hendin, B. AU - Huang, D. AU - Wray, S. AU - Naismith, R. T. AU - Rosenblatt, S. AU - Zambrano, J. PY - 2017 DA - 2017// TI - Subcutaneous peginterferon β-1a injection-site reaction experience and mitigation: Delphi analysis of the ALLOW study JO - Neurodegener Dis Manag VL - 7 UR - https://doi.org/10.2217/nmt-2016-0032 DO - 10.2217/nmt-2016-0032 ID - Hendin2017 ER - TY - STD TI - Plegridy®, Summary of Product Characteristics. http://ec.europa.eu/health/documents/community-register/2014/20140718129034/anx_129034_en.pdf. Accessed 3 Apr 2017. UR - http://ec.europa.eu/health/documents/community-register/2014/20140718129034/anx_129034_en.pdf ID - ref19 ER - TY - BOOK AU - Cui, Y. PY - 2016 DA - 2016// TI - ADVANCE phase 3 extension study (ATTAIN): Peginterferon beta-1a safety and tolerability remain favorable in RMS patients with up to 5 years of treatment. AAN ID - Cui2016 ER - TY - STD TI - Avonex®, Summary of Product Characteristics. https://www.ema.europa.eu/en/documents/product-information/avonex-epar-product-information_en.pdf Accessed 25 Apr 2019. UR - https://www.ema.europa.eu/en/documents/product-information/avonex-epar-product-information_en.pdf ID - ref21 ER - TY - STD TI - Rebif®, Summary of Product Characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000136/WC500048681.pdf. Accessed 3 Apr 2017. UR - http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000136/WC500048681.pdf ID - ref22 ER - TY - STD TI - Betaferon®, Summary of Product Characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000081/WC500053225.pdf. Accessed 3 Apr 2017. UR - http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000081/WC500053225.pdf ID - ref23 ER - TY - JOUR AU - Halper, J. AU - Centonze, D. AU - Newsome, S. D. AU - Huang, D. AU - Robertson, C. AU - You, X. PY - 2016 DA - 2016// TI - Management strategies for flu-like symptoms and injection-site reactions associated with Peginterferon Beta-1a JO - Int J MS Care VL - 18 UR - https://doi.org/10.7224/1537-2073.2015-042 DO - 10.7224/1537-2073.2015-042 ID - Halper2016 ER - TY - JOUR AU - Frohman, E. M. AU - Brannon, K. AU - Alexander, S. AU - Sims, D. AU - Phillips, J. T. AU - O’Leary, S. PY - 2004 DA - 2004// TI - Disease modifying agent related skin reactions in multiple sclerosis: prevention, assessment, and management JO - Mult Scler VL - 10 UR - https://doi.org/10.1191/1352458504ms1002oa DO - 10.1191/1352458504ms1002oa ID - Frohman2004 ER - TY - JOUR AU - Katsarava, Z. AU - Ehlken, B. AU - Limmroth, V. AU - Taipale, K. AU - Patel, S. N. AU - Niemczyk, G. PY - 2015 DA - 2015// TI - Adherence and cost in multiple sclerosis patients treated with IM IFN beta-1a: impact of the CARE patient management program JO - BMC Neurol VL - 15 UR - https://doi.org/10.1186/s12883-015-0426-x DO - 10.1186/s12883-015-0426-x ID - Katsarava2015 ER - TY - STD TI - A Pilot Study of Warm and Cold Compress to Reduce Injection Site Erythema Due to Peginterferon-beta-1a in MS - Full Text View - ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02490943?term=peginterferon+beta-1a&rank=11. Accessed 2 Apr 2017. UR - https://clinicaltrials.gov/ct2/show/NCT02490943?term=peginterferon+beta-1a&rank=11 ID - ref27 ER - TY - JOUR AU - Hawro, T. AU - Fluhr, J. W. AU - Mengeaud, V. AU - Redoulès, D. AU - Church, M. K. AU - Maurer, M. PY - 2014 DA - 2014// TI - Polidocanol inhibits cowhage - but not histamine-induced itch in humans JO - Exp Dermatol VL - 23 UR - https://doi.org/10.1111/exd.12555 DO - 10.1111/exd.12555 ID - Hawro2014 ER - TY - JOUR AU - Leroy, A. AU - Baeck, M. AU - Tennstedt, D. PY - 2011 DA - 2011// TI - Contact dermatitis and secondary systemic allergy to dimethindene maleate JO - Contact Dermatitis VL - 64 UR - https://doi.org/10.1111/j.1600-0536.2010.01830.x DO - 10.1111/j.1600-0536.2010.01830.x ID - Leroy2011 ER - TY - JOUR AU - Jocher, A. AU - Nist, G. AU - Weiss, J. M. AU - Wetzel, D. AU - Merfort, I. AU - Jakob, T. PY - 2009 DA - 2009// TI - Allergenic potential of Arnica-containing formulations in Arnica-allergic patients JO - Contact Dermatitis VL - 61 UR - https://doi.org/10.1111/j.1600-0536.2009.01638.x DO - 10.1111/j.1600-0536.2009.01638.x ID - Jocher2009 ER - TY - JOUR AU - Lanzillo, R. AU - Moccia, M. AU - Carotenuto, A. AU - Vacchiano, V. AU - Satelliti, B. AU - Panetta, V. AU - Brescia Morra, V. PY - 2015 DA - 2015// TI - Vitamin K cream reduces reactions at the injection site in patients with relapsing-remitting multiple sclerosis treated with subcutaneous interferon beta - VIKING study JO - Mult Scler VL - 21 UR - https://doi.org/10.1177/1352458514562989 DO - 10.1177/1352458514562989 ID - Lanzillo2015 ER - TY - JOUR AU - Casoni, F. AU - Merelli, E. AU - Bedin, R. AU - Martella, A. AU - Cesinaro, A. AU - Bertolotto, A. PY - 2003 DA - 2003// TI - Necrotizing skin lesions and NABs development in a multiple sclerosis patient treated with IFNbeta 1b JO - Mult Scler VL - 9 UR - https://doi.org/10.1191/1352458503ms933sr DO - 10.1191/1352458503ms933sr ID - Casoni2003 ER - TY - JOUR AU - Jacobs, L. D. AU - Cookfair, D. L. AU - Rudick, R. A. AU - Herndon, R. M. AU - Richert, J. R. AU - Salazar, A. M. PY - 1996 DA - 1996// TI - Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The multiple sclerosis collaborative research group (MSCRG) JO - Ann Neurol VL - 39 UR - https://doi.org/10.1002/ana.410390304 DO - 10.1002/ana.410390304 ID - Jacobs1996 ER - TY - STD TI - Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology. 1995;45:1277–85 http://www.ncbi.nlm.nih.gov/pubmed/7617182. Accessed 4 Sep 2016. UR - http://www.ncbi.nlm.nih.gov/pubmed/7617182 ID - ref34 ER - TY - JOUR PY - 2001 DA - 2001// TI - PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS JO - Neurology. VL - 56 UR - https://doi.org/10.1212/WNL.56.12.1628 DO - 10.1212/WNL.56.12.1628 ID - ref35 ER - TY - JOUR AU - Lublin, F. D. AU - Whitaker, J. N. AU - Eidelman, B. H. AU - Miller, A. E. AU - Arnason, B. G. AU - Burks, J. S. PY - 1996 DA - 1996// TI - Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference JO - Neurology. VL - 46 UR - https://doi.org/10.1212/WNL.46.1.12 DO - 10.1212/WNL.46.1.12 ID - Lublin1996 ER - TY - JOUR AU - Nadjar, Y. AU - Coutelas, E. AU - Prouteau, P. AU - Panzer, F. AU - Paquet, D. AU - Saint-Val, C. PY - 2011 DA - 2011// TI - Injection of interferon-beta in the morning decreases flu-like syndrome in many patients with multiple sclerosis JO - Clin Neurol Neurosurg VL - 113 UR - https://doi.org/10.1016/j.clineuro.2010.12.013 DO - 10.1016/j.clineuro.2010.12.013 ID - Nadjar2011 ER - TY - JOUR PY - 2005 DA - 2005// TI - The Goldman consensus statement on depression in multiple sclerosis JO - Mult Scler VL - 11 UR - https://doi.org/10.1191/1352458505ms1162oa DO - 10.1191/1352458505ms1162oa ID - ref38 ER - TY - JOUR AU - Minden, S. L. AU - Feinstein, A. AU - Kalb, R. C. AU - Miller, D. AU - Mohr, D. C. AU - Patten, S. B. PY - 2014 DA - 2014// TI - Evidence-based guideline: assessment and management of psychiatric disorders in individuals with MS: report of the guideline development Subcommittee of the American Academy of neurology JO - Neurology. VL - 82 UR - https://doi.org/10.1212/WNL.0000000000000013 DO - 10.1212/WNL.0000000000000013 ID - Minden2014 ER - TY - JOUR AU - Feinstein, A. PY - 2000 DA - 2000// TI - Multiple sclerosis, disease modifying treatments and depression: a critical methodological review JO - Mult Scler J VL - 6 UR - https://doi.org/10.1177/135245850000600509 DO - 10.1177/135245850000600509 ID - Feinstein2000 ER - TY - JOUR AU - Schippling, S. AU - O’Connor, P. AU - Knappertz, V. AU - Pohl, C. AU - Bogumil, T. AU - Suarez, G. PY - 2016 DA - 2016// TI - Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial JO - J Neurol VL - 263 UR - https://doi.org/10.1007/s00415-016-8146-8 DO - 10.1007/s00415-016-8146-8 ID - Schippling2016 ER - TY - JOUR AU - Goeb, J. L. AU - Even, C. AU - Nicolas, G. AU - Gohier, B. AU - Dubas, F. AU - Garré, J. B. PY - 2006 DA - 2006// TI - Psychiatric side effects of interferon-beta in multiple sclerosis JO - Eur Psychiatry VL - 21 UR - https://doi.org/10.1016/j.eurpsy.2005.09.013 DO - 10.1016/j.eurpsy.2005.09.013 ID - Goeb2006 ER - TY - JOUR AU - Goëb, J. L. AU - Cailleau, A. AU - Lainé, P. AU - Etcharry-Bouyx, F. AU - Maugin, D. AU - Duverger, P. h. AU - Gohier, B. AU - Rannou-Dubas, K. AU - Dubas, F. AU - Garré, J. B. PY - 2003 DA - 2003// TI - Acute Delirium, Delusion, and Depression During IFN-β-1a Therapy for Multiple Sclerosis: A Case Report JO - Clinical Neuropharmacology VL - 26 UR - https://doi.org/10.1097/00002826-200301000-00002 DO - 10.1097/00002826-200301000-00002 ID - Goëb2003 ER - TY - JOUR AU - Pandya, R. AU - Patten, S. PY - 2002 DA - 2002// TI - Depression in multiple sclerosis associated with interferon beta-1a (Rebif) JO - Can J Psychiatr VL - 47 UR - https://doi.org/10.1177/070674370204700720 DO - 10.1177/070674370204700720 ID - Pandya2002 ER - TY - JOUR AU - Patti, F. AU - Amato, M. P. AU - Trojano, M. AU - Bastianello, S. AU - Tola, M. R. AU - Picconi, O. PY - 2011 DA - 2011// TI - Quality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive impairment in MUltiple sclerosis) study JO - Mult Scler VL - 17 UR - https://doi.org/10.1177/1352458511401943 DO - 10.1177/1352458511401943 ID - Patti2011 ER - TY - JOUR AU - Jong, H. AU - Kingwell, E. AU - Shirani, A. PY - 2017 DA - 2017// TI - Evaluating the safety of b-interferons in MS JO - Neurology VL - 88 UR - https://doi.org/10.1212/WNL.0000000000004037 DO - 10.1212/WNL.0000000000004037 ID - Jong2017 ER - TY - JOUR AU - Vial, T. AU - Descotes, J. PY - 1994 DA - 1994// TI - Clinical toxicity of the interferons JO - Drug Saf VL - 10 UR - https://doi.org/10.2165/00002018-199410020-00003 DO - 10.2165/00002018-199410020-00003 ID - Vial1994 ER - TY - JOUR AU - Rieckmann, P. AU - O’Connor, P. AU - Francis, G. S. AU - Wetherill, G. AU - Alteri, E. PY - 2004 DA - 2004// TI - Haematological effects of interferon-beta-1a (Rebif) therapy in multiple sclerosis JO - Drug Saf VL - 27 UR - https://doi.org/10.2165/00002018-200427100-00005 DO - 10.2165/00002018-200427100-00005 ID - Rieckmann2004 ER - TY - JOUR AU - Tremlett, H. AU - Oger, J. PY - 2004 DA - 2004// TI - Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosis JO - J Neurol VL - 251 UR - https://doi.org/10.1007/s00415-004-0619-5 DO - 10.1007/s00415-004-0619-5 ID - Tremlett2004 ER - TY - JOUR AU - Monzani, F. AU - Caraccio, N. AU - Dardano, A. AU - Ferrannini, E. PY - 2004 DA - 2004// TI - Thyroid autoimmunity and dysfunction associated with type I interferon therapy JO - Clin Exp Med VL - 3 UR - https://doi.org/10.1007/s10238-004-0026-3 DO - 10.1007/s10238-004-0026-3 ID - Monzani2004 ER - TY - JOUR AU - Klotz, L. AU - Berthele, A. AU - Brück, W. AU - Chan, A. AU - Flachenecker, P. AU - Gold, R. PY - 2016 DA - 2016// TI - Monitoring von Blutparametern unter verlaufsmodifizierender MS-Therapie JO - Nervenarzt. VL - 87 UR - https://doi.org/10.1007/s00115-016-0077-1 DO - 10.1007/s00115-016-0077-1 ID - Klotz2016 ER - TY - STD TI - Qualitätshandbuch Multiple Sklerose. http://www.kompetenznetz-multiplesklerose.de/wp-content/uploads/2016/12/KKNMS_Handbuch_Gesamtausgabe_verknuepft_20160914_webfrei.pdf. Accessed 17 Dec 2016. UR - http://www.kompetenznetz-multiplesklerose.de/wp-content/uploads/2016/12/KKNMS_Handbuch_Gesamtausgabe_verknuepft_20160914_webfrei.pdf ID - ref52 ER -